- 8. (Amended) A process for preparing a compound according to claim 1 which process comprises:
 - a) reacting compounds of formula (II):

where R^a is a group R³ as defined in claim 1 or protected form of a group R³, R^b is hydrogen or a hydroxy protecting group, and R1 and R2 are as defined in claim 1, with a compound of formula (III):

where T and ring A are as defined in claim 1, and L is a displaceable group; and thereafter optionally:

- i) removing any protecting groups; and/or
- ii) forming a pharmaceutically acceptable salt or prodrug thereof.

Please cancel claim 10, without prejudice, and add the following new method claims:



- 11. (New) A method treating a disease or medical condition mediated by monocyte chemoattractant protein-1 (MCP-1) in a warm blooded animal in need of such treatment, said method comprising administering to said animal a MCP-1 inhibitory effective amount of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or prodrug thereof.
 - 12. (New) The method of claim 11 wherein said disease is inflammatory disease.

ATTORNEY DOCKET NO.: 056291-5041 Application No.: 09/889,599

7009,399

Page 3

13. (New) A method treating a disease or medical condition mediated by <u>Regulated</u> upon <u>Activation</u>, <u>Normal T-cell Expressed and Secreted (RANTES) induced chemotaxis in a warm blooded animal in need of such treatment, said method comprising administering to said animal a RANTES induced chemotaxis inhibitory effective amount of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or prodrug thereof.</u>

- 14. (New) The method of claim 13 wherein said disease or medical condition is inflammatory disease.
- 15. (New) A method for producing an anti-inflammatory effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or prodrug thereof.
- 16. (New) A method for producing a MCP-1 inhibitory effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or prodrug thereof.
- 17. (New) A method for producing a RANTES induced chemotaxis inhibitory effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or prodrug thereof.

